Soliton
Soliton was a Houston-based medical aesthetics company developing non-invasive body sculpting technology for aesthetic medicine practices and healthcare providers, acquired by Allergan Aesthetics (AbbVie) in December 2021.
- Company typePrivate
- Founded2012
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Soliton does
Soliton was a medical aesthetics company developing non-invasive body contouring technology for healthcare providers and aesthetic medicine practices. The company's core technology focused on body fat reduction and body sculpting without surgery, addressing multibillion-dollar market opportunities in the non-invasive aesthetic procedure category. Soliton was co-founded by Walter V. Klemp (Executive Chairman) and Chris Capelli (Co-Founder, CEO and CSO, Director), headquartered in Houston, Texas, and traded publicly on NASDAQ under the symbol SOLY.
The company pursued a horizontal go-to-market strategy targeting aesthetic medicine practices and healthcare providers broadly, rather than concentrating on a narrow vertical. Across 2012-2019, Soliton raised approximately $13.45 million across four funding rounds, with Remeditex Ventures leading the largest $9.45M round in June 2019. The company operated with 11-50 employees, consistent with an early-stage device developer focused on technology development and pre-commercial activities.
In December 2021, Allergan Aesthetics — an AbbVie subsidiary — acquired Soliton to expand its portfolio of non-invasive body sculpting procedures, integrating the technology alongside brands such as CoolSculpting and CoolTone. Following the transaction, Soliton ceased to operate as an independent entity and became part of Allergan Aesthetics' broader aesthetic medicine portfolio. No AI/ML capabilities, detailed product specifications, or revenue figures were disclosed in the available source material.
Soliton firmographics
Firmographics- Name
- Soliton
- Website
- https://soliton.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Soliton was a Houston-based medical aesthetics company developing non-invasive body sculpting technology for aesthetic medicine practices and healthcare providers, acquired by Allergan Aesthetics (AbbVie) in December 2021.
- Ownership category
- akta.pro rank
Soliton industry classification
Industry- Product category
- Medical Aesthetics Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Body Contouring & Non-Invasive Aesthetic Recovery (e.g., Lymphatic Drainage) (HSADAKAM)
- akta.pro secondary industries
- Detox, Lymphatic & Body Contouring Treatments (Non-Medical) (HSALAFAJ), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)
Keywords
Where Soliton is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
Soliton business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Soliton product offering
Product offeringCore offering
Soliton developed non-invasive body sculpting technology for aesthetic medicine, enabling body fat reduction and body contouring without surgery. The technology was designed to expand the portfolio of non-invasive aesthetic procedures available to medical providers. Following the December 2021 acquisition, Soliton's technology became part of Allergan Aesthetics' body contouring treatment offerings.
Product overview
Soliton offers a unified endpoint management software platform called Soliton Secure Workspace, designed specifically for BYOD (Bring Your Own Device) environments. This UEM solution enables organizations to centralize device monitoring, security, and management across diverse operating systems and device types from a single console, addressing key challenges organizations face in BYOD scenarios including device diversity, user privacy concerns, and policy complexity. The company was acquired by Allergan Aesthetics (an AbbVie company) in December 2021.
Differentiator
Problem solved
Functional benefit
Products and services
- Non-invasive body sculpting technology
Companies that use Soliton
Customer profileSegments1 record
Ideal customer profiles1 record
Soliton technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Soliton partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights1 record
Soliton competitors and assessment
Company assessmentDirect peers
- Venus Concept: Venus Concept markets non-invasive body contouring and skin tightening platforms (e.g., Venus Bliss) directly to aesthetic and medspa providers. Targets the same non-invasive fat reduction indications as Soliton.
- BTL Aesthetics (Emsculpt/Emsculpt NEO): BTL markets Emsculpt and Emsculpt NEO, non-invasive body sculpting devices using HIFEM and radiofrequency to reduce fat and build muscle. BTL is arguably Soliton's most aggressive direct competitor in the body-contouring procedure category.
- Cynosure (SculpSure): Cynosure's SculpSure is a non-invasive laser-based body contouring system targeting similar indications (subcutaneous fat reduction). Direct product overlap makes Cynosure a primary competitive comparable for Soliton's technology.
- InMode: InMode offers a suite of minimally and non-invasive aesthetic platforms, including body contouring and skin remodeling devices. Competes in the same physician-dispensed channel and overlapping procedure indications.
- Cutera (truSculpt): Cutera's truSculpt platform uses radiofrequency for non-invasive fat reduction and body sculpting. Operates in the same provider channel (aesthetic practices) with overlapping clinical use cases, making it a strong product-level peer.
- Solta Medical (Liposonix): Solta's Liposonix is a non-invasive ultrasound-based fat-reduction device. Closely comparable mechanism (acoustic energy for body contouring) and similar target customer base of aesthetic practices.
Broad incumbents
- Allergan Aesthetics (CoolSculpting): Allergan's own CoolSculpting platform is the most direct internal comparable — it pioneered non-invasive cryolipolysis fat reduction. Now Soliton's corporate sibling rather than a competitor, CoolSculpting defines the standard Soliton's technology must differentiate against within Allergan's portfolio.
- AbbVie (parent context): AbbVie, through its Allergan Aesthetics division, is Soliton's parent company and the broadest incumbent in the medical aesthetics space. Relevant for understanding Soliton's distribution, R&D, and capital allocation environment.
Emerging players
- Classys (Clatuu/Clostridium): South Korea-based Classys markets Clatuu Alpha, a non-invasive cryolipolysis body contouring device. Geographic and technological overlap make it a relevant emerging-player peer, particularly for global expansion scenarios.
Others
- Zeltiq Aesthetics (legacy): Zeltiq was the original developer of cryolipolysis (CoolSculpting) before being acquired by Allergan. Useful historical comparable for how a single non-invasive body sculpting technology can scale into a flagship aesthetic franchise.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Soliton social profiles
Digital presenceSoliton financial estimates
Financial estimateRevenue estimate
Valuation estimate
Soliton leadership team
Management profileNumber of profiles
Profiles2 records
Soliton funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Soliton M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Soliton
What does Soliton do?
Soliton developed non-invasive body sculpting technology for aesthetic medicine, enabling body fat reduction and body contouring without surgery. The technology was designed to expand the portfolio of non-invasive aesthetic procedures available to medical providers. Following the December 2021 acquisition, Soliton's technology became part of Allergan Aesthetics' body contouring treatment offerings.
Is Soliton a public or private company?
Soliton is a private company. It is classified as corporate owned and is currently acquired.
When was Soliton founded?
Soliton was founded in 2012. It employs 11 to 50 people.
Where is Soliton based?
Soliton is headquartered in Houston, United States, in the North America region.
Who are Soliton's main competitors?
Direct peers on record are Venus Concept, BTL Aesthetics (Emsculpt/Emsculpt NEO), Cynosure (SculpSure), InMode, Cutera (truSculpt) and Solta Medical (Liposonix). Broad incumbents are Allergan Aesthetics (CoolSculpting) and AbbVie (parent context). Classys (Clatuu/Clostridium) is listed as an emerging player. Zeltiq Aesthetics (legacy) is listed as an others.
Does Soliton have an API?
No public API is recorded for Soliton.
What industry is Soliton in?
Soliton's product category is Medical Aesthetics Devices. Its primary akta.pro industry code is HSADAKAM, Body Contouring & Non-Invasive Aesthetic Recovery (e.g., Lymphatic Drainage), with a secondary code of HSALAFAJ, Detox, Lymphatic & Body Contouring Treatments (Non-Medical). Its NAICS code is 339113 and its SIC code is 3841.